Related Experiment Video
Updated: Aug 5, 2025

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
Enveloped viruses pseudotyped with mammalian myogenic cell fusogens target skeletal muscle for gene delivery
Sajedah M Hindi1, Michael J Petrany1, Elena Greenfeld2
1Division of Molecular Cardiovascular Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Abstract:
Entry of enveloped viruses into cells is mediated by fusogenic proteins that form a complex between membranes to drive rearrangements needed for fusion. Skeletal muscle development also requires membrane fusion events between progenitor cells to form multinucleated myofibers. Myomaker and Myomerger are muscle-specific cell fusogens, but do not structurally or functionally resemble classical viral fusogens. We asked if the muscle fusogens could functionally substitute for viral fusogens, despite their structural distinctiveness, and fuse viruses to cells. We report that engineering of Myomaker and Myomerger on the membrane of enveloped viruses leads to specific transduction of skeletal muscle. We also demonstrate that locally and systemically injected virions pseudotyped with the muscle fusogens can deliver micro-Dystrophin (μDys) to skeletal muscle of a mouse model of Duchenne muscular dystrophy. Through harnessing the intrinsic properties of myogenic membranes, we establish a platform for delivery of therapeutic material to skeletal muscle.
Insights
Researchers engineered muscle fusion proteins Myomaker and Myomerger onto enveloped viruses. This enables specific delivery of therapeutic micro-Dystrophin to skeletal muscle cells in a Duchenne muscular dystrophy model.
Area of Science:
- Biochemistry
- Molecular Biology
- Cell Biology
Background:
- Viral entry relies on fusogenic proteins mediating membrane fusion.
- Skeletal muscle development involves cell fusion via muscle-specific fusogens, Myomaker and Myomerger.
- These muscle fusogens differ structurally and functionally from viral fusogens.
Conclusions:
- Muscle fusogens Myomaker and Myomerger can mediate virus-cell fusion.
- This engineered viral system achieves targeted skeletal muscle gene delivery.
- A new platform for skeletal muscle therapeutic delivery is established.

